Key clinical point:
Major finding: The rate of freedom from distant metastasis at 3 years was 77.8% with twice-daily radiation plus 5-flourouracil-cisplatin and 84.0% with daily radiation plus gemcitabine.
Data source: A multicenter randomized phase 2 trial among 70 patients with muscle-invasive (cT2-4a) bladder cancer who had undergone TURBT (NRG/RTOG 0712 trial).
Disclosures: Dr. Coen disclosed that he had no relevant conflicts of interest. The trial was supported by the National Cancer Institute.
Source: Coen, J. et al, 2018 Genitourinary Cancers Symposium, Abstract 408
Coen, J. et al, 2018 Genitourinary Cancers Symposium, Abstract 408
This Week's Must Reads
How do you pronounce that drug name?, Frank D. JAMA Intern Med. 2018;178(3):319-320. doi:10.1001/jamainternmed.2017.7898
'Glass ceiling' extends to biomedical industry payments, Tringale K and Hattangadi-Gluth J. JAMA Intern Med. 2018;178(3):421-423. doi:10.1001/jamainternmed.2017.7445
Mining social media to detect adverse drug reactions to newly-approved drugs, Ransohoff J et al. JAMA Oncology March 1, 2018. doi:10.1001/jamaoncol.2017.5688
Insurance type linked to cancer care delays, Wharam et al. J Clin Oncol. 2018 Feb 28. doi: 10.1200/JCO.2017.75.2501.
Intervention boosted the rate of colorectal cancer screening, Source: Miller, D et al. Ann Inter Med 2018. DOI: 10.7326/M17-2315
Must Reads in Renal Cell Carcinoma
Six factors predict urothelial cancer response, Pond GR et al. GU Cancers Symposium Abstract 413
Combo bests single therapy in metastatic RCC, Motzer RJ et al. GU Cancers Symposium Abstract 578
Chemo is best course in resected urothelial disease, Birtle A et al. Genitourinary Cancers Symposium. Abstract 407.
Selecting chemoradiation in bladder cancer, Coen, J. et al, 2018 Genitourinary Cancers Symposium, Abstract 408.
When to choose surgery or surveillance in RCC, Hakimi A et al. J Urol. 2018 Feb 26 doi: 10.1016/j.juro.2018.02.3087.